van der Vorst 2019.

Methods	Randomised controlled trial
Participants	Hospitalised patients with advanced cancer diagnosed with delirium (DSM‐IV‐TR) 100 participants randomised between January 2011 and June 2016 Olanzapine (n = 50); haloperidol (n = 50)
Interventions	Olanzapine versus haloperidol
Outcomes	Primary outcome: Delirium response rate (DRR) defined as the Delirium Rating Scale‐Revised‐98 (DRS‐R‐98) total severity score < 15.25 points and ≥ 4.5 points reduction Secondary outcomes: Time to response Tolerability Delirium‐related distress (assessed by the Delirium Experience Questionnaire)
Notes	Responsible party: H.M.W. Verheul, VU University Medical Center. ClinicalTrials.gov identifier: NCT01539733 Conference abstract published: van der Vorst 2018. Full paper unpublished at time of search (8 July 2019), but subsequently published on 4 December 2019 (van der Vorst 2019)